Healthcare Industry News: schizophrenia
News Release - August 15, 2008
XENAZINE(R) (Tetrabenazine) Approved by FDA for Patients with Chorea Associated with Huntington's DiseaseWASHINGTON, Aug. 15 (HSMN NewsFeed) -- Prestwick Pharmaceuticals, Inc., a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved XENAZINEŽ (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). XENAZINE is the first and only FDA-approved treatment for any symptom of HD and is expected to be available later this year.
"Until today, physicians and patients had no FDA-approved treatments for Huntington's disease," said Fred Marshall, M.D., chief of the geriatric neurology unit at the University of Rochester. "Within a few months, for the first time, physicians will be able to offer these critically-ill patients a safe and effective medication to treat their chorea."
A double-blind, placebo-controlled, Phase 3 study found that XENAZINE significantly reduced patients' chorea burden, improved global outcome scores, and was generally safe and well tolerated. XENAZINE will be marketed under an FDA-approved Risk Evaluation and Mitigation Strategy to decrease the risk of depression and suicidal ideation that may be associated with the drug, and are often pre-existing conditions in Huntington's disease patients.
In December 2007, patients, advocates, and caregivers spoke in favor of approving XENAZINE at a meeting of the FDA's Peripheral and Central Nervous System Drugs Advisory Committee. The committee voted 11-0 to recommend approval of the drug.
"We are pleased that the FDA has approved XENAZINE, the first medication for the Huntington's disease patients and physicians who are in desperate need of a treatment," said George F. Horner, III, president and chief executive officer of Prestwick. "The approval of XENAZINE is a huge advancement for the HD community, and we thank them for their contributions in helping to make this important product available in the United States."
XENAZINE has been available in a number of countries in Europe for more than 30 years.
About Huntington's Disease
Affecting an estimated 30,000 Americans, HD is a devastating neurodegenerative disease that causes progressive movement disorders, cognitive dysfunction and behavioral changes and is ultimately a fatal condition. Chorea is the most common symptom, affecting approximately 90% of HD patients, and is characterized by excessive, involuntary and repetitive movements, which are the most visible and dangerous manifestations of HD and interfere with patients' abilities to perform activities of daily living, including dressing, bathing and caring for themselves. For more information about HD, please visit http://www.hdfoundation.org or http://www.hdsa.org.
About XENAZINE (tetrabenazine)
XENAZINE is indicated for the treatment of chorea associated with Huntington's disease. A selective and reversible centrally-acting dopamine depleting drug, XENAZINE works by inhibiting a molecule known as VMAT2 (vesicular monoamine transporter 2). XENAZINE has been designated as an "orphan drug" by the FDA and will have seven years market exclusivity in the United States. Full prescribing information will be available at http://www.prestwickpharma.com in the near future.
Important Safety Information
The most frequent and serious adverse events seen with tetrabenazine are somnolence/sedation and insomnia, respectively. Adverse events reported with XENAZINE included depression, akathisia, parkinsonism and sedation. XENAZINE's effects are largely reversible and manageable.
Prestwick Pharmaceuticals, a privately-held pharmaceutical company headquartered in Washington, DC, is currently managing product candidates for CNS conditions with significant unmet needs, including Huntington's disease, schizophrenia, and sleep apnea. For more information, go to http://www.prestwickpharma.com.
Source: Prestwick Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.